Drug Search Results
More Filters [+]

Bendroflumethiazide

Alternative Names: bendroflumethiazide, bendrofluazide, corzide, naturetin-2.5, naturetin-10, naturetin-5
Latest Update: 2023-09-28
Latest Update Note: Clinical Trial Update

Product Description

A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. Bendroflumethiazide is a sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group. It has a role as a diuretic and an antihypertensive agent. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bendroflumethiazide)

Mechanisms of Action: Potassium Channel Blocker,NKCC Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Canada | Denmark | France | Greece | Iceland | India | Ireland | Italy | Malta | New Zealand | Norway | Pakistan | Portugal | Spain | Sweden | Taiwan | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bendroflumethiazide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title